



# MTN Closing Ceremony

---

**Sharon Hillier and Jared Baeten**  
**September 21, 2017**

Cape Town, South Africa

# What Have We Learned This Week?

- Young women can use the ring
- Young women want choices, and they see the ring and oral PrEP as good choices
  - Ring less medicalized
  - Oral pills less scary and more familiar
- We need to do more to help communities to be more supportive about engaging in prevention!
- These are the people we serve!

# Regional Consultation 2016





# Zimbabwe Meeting 2017





# South Africa Meeting 2017





# Uganda Meeting 2017



# What We Have Learned

- The road to licensure for the ring is long and difficult
  - We will send our support to our family as they go through these audits
- There are many lessons to be learned about how PrEP is being rolled out which can help us understand what we will need to do with the ring.
- The next generation rings which last longer and which could provide contraception are on their way

# What we have learned...

---

- The injectable ARV cabotegravir is just beginning phase 3 clinical trials
  - Results are years away and if it works well, regulatory approval is many years beyond that
- Implants, although very exciting as an idea, are still very early in development and are even farther behind in development
- The bottom line: these potential options are years away




# Planning for the Future is NOW!



Tuesday, September 12, 2017

## NIH HIV/AIDS Network Refinement Update: Focusing the Science-Driven HIV Research Enterprise



---

Every 7 years, NIH competitively renews its funding of the HIV/AIDS clinical research networks operating in the United States and internationally. In a [new blog post](#), NIAID Division of AIDS Director Dr. Carl Dieffenbach describes how NIH can most effectively refine the HIV research enterprise to hasten an end to the pandemic. The NIH HIV research agenda is grounded in three

# From Carl Dieffenbach.....

- We have effective prevention tools: daily oral PrEP), PEP, voluntary medical male circumcision, and a dapivirine vaginal ring.
- Criteria for future development:
  - safe, desired and highly effective
  - **should provide systemic protection irrespective of route of exposure** (long-acting injectables, implantables and sustained-release oral formulations)

# Is there still room for topical microbicides?

- How important is choice?
- Will everyone who needs prevention be willing to choose to be on a systemic ARV or antibody?
- Is there a role for products like the ring which can only protect women from vaginal sex?
- Is there a role for on-demand products for women and men? And MPTs?
- Will we end the HIV epidemic with the tools we have now?



# Please Share Your Views with DAIDS

- You can send your comments directly by email to

[NIAIDnetworkrefinement@mail.nih.gov](mailto:NIAIDnetworkrefinement@mail.nih.gov)

- Or through this link:

<https://www.niaid.nih.gov/forms/refining-hiv-research-enterprise-response-form>

# THANK YOU

---

- For your passion
- For your energy
- For all that you do every day!